Swiss National Bank’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-69,900
| Closed | -$6.78M | – | 2576 |
|
|
2019
Q3 | $6.78M | Hold |
69,900
| – | – | 0.01% | 932 |
|
|
2019
Q2 | $7.16M | Buy |
69,900
+8,000
| +13% | +$863K | 0.01% | 913 |
|
|
2019
Q1 | $7.05M | Buy |
61,900
+2,100
| +4% | +$154K | 0.01% | 894 |
|
|
2018
Q4 | $2.34M | Buy |
59,800
+1,500
| +3% | +$65.1K | ﹤0.01% | 1460 |
|
|
2018
Q3 | $3.18M | Hold |
58,300
| – | – | ﹤0.01% | 1418 |
|
|
2018
Q2 | $4.83M | Buy |
58,300
+3,600
| +7% | +$278K | 0.01% | 1128 |
|
|
2018
Q1 | $3.64M | Buy |
54,700
+3,300
| +6% | +$191K | ﹤0.01% | 1248 |
|
|
2017
Q4 | $2.64M | Hold |
51,400
| – | – | ﹤0.01% | 1466 |
|
|
2017
Q3 | $4.58M | Buy |
51,400
+12,200
| +31% | +$926K | 0.01% | 1070 |
|
|
2017
Q2 | $2.34M | Buy |
39,200
+1,500
| +4% | +$83.8K | ﹤0.01% | 1486 |
|
|
2017
Q1 | $2.01M | Hold |
37,700
| – | – | ﹤0.01% | 1564 |
|
|
2016
Q4 | $1.88M | Buy |
37,700
+1,200
| +3% | +$64.3K | ﹤0.01% | 1594 |
|
|
2016
Q3 | $2.19M | Sell |
36,500
-100
| -0.3% | -$5.76K | ﹤0.01% | 1441 |
|
|
2016
Q2 | $1.87M | Buy |
36,600
+6,900
| +23% | +$295K | ﹤0.01% | 1552 |
|
|
2016
Q1 | $846K | Buy |
29,700
+8,500
| +40% | +$268K | ﹤0.01% | 2008 |
|
|
2015
Q4 | $961K | Buy |
21,200
+10,200
| +93% | +$535K | ﹤0.01% | 1848 |
|
|
2015
Q3 | $459K | Buy |
11,000
+1,400
| +15% | +$73.1K | ﹤0.01% | 2215 |
|
|
2015
Q2 | $579K | Buy |
+9,600
| New | +$635K | ﹤0.01% | 2155 |
|
Swiss National Bank's ONCE Position: Q4 2019 in Review
Swiss National Bank sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 69,900 shares — an estimated $6.78M sold.
Swiss National Bank first reported a position in ONCE in Q2 2015 and held it in 18 quarters. The position peaked at $7.16M in Q2 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.
- Swiss National Bank reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- Swiss National Bank sold 69,900 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $6.78M.
- Swiss National Bank first reported a position in Spark Therapeutics, Inc. Common Stock in Q2 2015 and held it in 18 quarters.
- Swiss National Bank's Spark Therapeutics, Inc. Common Stock position peaked at $7.16M in Q2 2019.
- 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.
Based on Swiss National Bank's 13F filing for Q4 2019, filed 6 Feb 2020.